11/4/2026

speaker
Operator
Conference Call Operator

Please stand by. Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet third quarter 2026 earnings conference call. If anyone needs assistance at any time during the conference, please press the star followed by the zero. As a reminder, this conference is being recorded today, November 4th, 2026. Following today's presentation, there will be a question and answer session. At this time, all participants are in a listen-only mode. If you have a question, please press the star followed by the one on your push-button phone. I would now like to turn the conference over to David DeMartino, Senior Vice President, Investor Relations. Please go ahead.

speaker
David DeMartino
Senior Vice President, Investor Relations

Thank you, Operator, and good morning, everyone. Welcome to Zero Vibe Life's third quarter 2026 earnings conference call. Joining me on today's call are Ivan Tornos, our Chairman President and CEO, and Paul Stellato, our Interim CFO and VP Controller and Chief Accounting Officer. Before we get started, I'd like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by the forward-looking statements due to a variety of risks and uncertainties. For a detailed discussion of all these risks and uncertainties, in addition to the inherent limitations of such forward-looking statements, please refer to our ICC filings. Please note, we assume no obligation to update these forward-looking statements, even if actual results or future expectations change materially. Additionally, the discussions on this call will include certain non-GAAP financial measures, some of which are probably looking non-GAAP financial measures. Reconciliation on these measures to the most directly comparable GAAP financial measures and an explanation of our basis for calculating these measures is included within our third quarter earnings release, which can be found on our website, seymourbiomet.com. With that, I'll turn the call over to Ivan. Ivan?

speaker
Ivan Tornos
Chairman, President and Chief Executive Officer

Thank you, David. Good morning, everyone, and thank you for joining today's call. I would like to start, as I always do, by thanking the more than 17,000 global Zimmer Biomed team members for your commitment, your resilience, and most importantly, your dedication to serving our customers and their patients each and every day. I'm grateful to work alongside you and I'm proud of the noble work we do to alleviate pain and improve the quality of life for people around the world. Roughly six months from now, We'll be celebrating our 100-year anniversary as a company. And as I often tell all of you, we are just getting started. Our boldest chapter remains ahead. During my prepared remarks this morning, I'll cover three things. First, I'll review our third quarter performance. Second, I'll discuss or increase outlook for 2026. And third, I'll provide an update on our three strategic priorities, which remain the same. People and Culture, Operational Excellence, and Innovation and Diversification. To begin, we delivered total net sales of $2.63 billion, resulting in 3.1% reported growth and 3.7% constant currency growth in the quarter, compared to the third quarter of 2025. Excluding the negative impact of our China distributor network consolidation strategy, A one-time headwind in fiscal year 2026, our constant currency growth in the quarter will have been 4.7%. Notably, in the period, two-thirds of our bulk of business grew at least upper single-digit or double-digit rates, validating the strength of our innovation cycle, the improvement in our commercial execution efforts, and the resilience of our global market environment. In addition, these results are a testament to our efforts to diversify our portfolio over the last six years as we continue to shift from a primarily joint reconstruction company to a broadly diversified business with leading platforms across SET, technology, and higher growth segments within core orthopedics. We are very proud of these quarter results as our hips and SET businesses grew upper single digits and technology and data, both cement and surgical, grew in the teens, driven by 20% growth in robotics, data and AI solutions. Furthermore, we are thrilled with the performance of a Paragon 28 acquisition, which continues to grow at roughly three times the foot and ankle market, approaching 20% growth, which we do believe is sustainable. Altogether, this broad-based performance More than offset the expected challenges in our new business and China. Turning to our product categories and starting with hips, our global hip business grew 7% on a constant currency basis in the third quarter, with growth of 5.8% in the U.S. and 8.2% internationally. U.S. hip growth continues to be driven by our new product, Cycle Strength, which includes Z1 or triple taper hip stem which now represents over 50% of all US hip stems up from about 40% in the second quarter of this year. Hemer or surgical impactor which is now being used in nearly 30% of all US primary hip cases is also a major catalyst. And third, OrthoGrip. which delivered its strongest quarter to date with over two-thirds of sales coming from recurring revenue. OrthoGrid is a clear differentiator for Zimmer Biomed and we look forward to its global expansion. Outside the U.S., we continue to build momentum with our iodine-coated hip stem ANCAP in Japan. This launch has far exceeded our high expectations and we are rapidly increasing supply to meet the greater than expected demand from both existing customers and the new accounts that we're opening. In addition, we're working on launch plans for other geographies outside of Japan. Turning to needs, as anticipated, the need business continued to face headwinds during the quarter, with sales declining 2.6% on a constant currency basis, including decreases of 2% in the U.S. and 3.4% The U.S. results reflect the non-impact of our Salesforce transition and a highly competitive knee implant market, while international needs continue to face pressure, most significantly from China headwinds, with which global needs will have been flat year over year this last third quarter. While we continue to expect ongoing pressure in the near term in our knee business, we are confident in our strategy and plan to return to sustainable growth over the long term by, number one, improving commercial execution. It's important to know that the U.S. Salesforce transition is nearing the halfway mark, and we're starting to see pockets of meaningful improvement across a variety of U.S. territories. Second, expanding our suite of robotics and enabling technology to meet the diverse needs of a wide array of surgeons around the world. We recently announced a multi-year limited distribution and supply agreement with Think Surgical to distribute an exclusive version of the only wireless handheld T-Mini miniature robotic system compatible with persona.ne. Most excitingly, we expect to file Monogram's 510K application with the FDA very soon, which is significantly ahead of schedule. We now anticipate that we can launch a surgeon-guided, fully autonomous version of Monogram in the first half of 2027, as opposed to the original expectation of a 2028 launch. We truly believe that this technology will represent a dramatic leap forward for the future of orthopedic care. We will be bringing Monogram to the American Association of Hip and Knee Surgeons annual meeting later this week in Dallas to obtain additional feedback on the systems workflow from surgeons. Our plan to have at least 225 robotic cells specialists also remains very much on track. From a global standpoint, the China-related headwinds, with anniversary in January of 2027, giving us visibility into improved global knee performance. SET accelerated to 7.1% growth on a constant currency basis in the quarter, including mid-single-digit growth in the U.S. We continue to see strength across our key franchises, including Furan Anko, Sports Medicine, CMFT, Cranial, Maxillofacial, Thoracic, and Upper Extremities, all of which grew between mid-single digits and high teens in the period. Critically, Paragon 28 cells grew over 18%, demonstrating the successful integration of the business and representing a blueprint for future acquisitions. These results were partially offset by continued pressure in trauma and restorative therapies. both of which declined in the quarter as expected. Technology and data, both cement and surgical, grew 13% on a constant currency basis in the third quarter, once again led by the strong demand for robotic offerings, including ROSA with Optimize and T-mini. Technology and data sales increased over 30% in the US, which validated a strategy of offering a comprehensive suite of Customer Centric Solutions to Surgeons. Turning now to our updated outlook for the remainder of 2026. With three solid quarters behind and an organic constant currency growth rate of 3.5% year to date, we are once again increasing our full year outlook. We are now raising our organic constant currency sales growth guidance to a range of 3% to 3.5% from 2.25% to 3.25% and raising also or adjusted earnings per share guidance to $8.50 to $8.60 from the previous guidance of $8.47 to $8.59. This increased outlook captures or expectations for consistent global market dynamics, ongoing risk of US sales force disruption, China-related headwinds to the tune of nearly 100 basis points in the fourth quarter, and roughly 50 basis points for the full year 2026, as well as continued pressure in this. With that, let's turn to our three strategic priorities, people and culture, Operational Excellence and Innovation and Diversification. First, people and culture. We continue to make steady progress as we transition to a fully dedicated and specialized sales force in the U.S. We started this initiative in earnest earlier this year, and I'm happy to share that three quarters into an eight-quarter journey We are proceeding ahead of our expectations with over 75% of our US sales force now being fully dedicated. While we are seeing some disruption associated with this transition, particularly in our new franchise, overall, it has been less disruptive than we initially anticipated. As part of this strategy, we continue to add sales reps across key growth franchises such as upper extremities, We're going to continue to invest back into the business to support a smooth transition. And we're going to manage this project with the rigor that it requires. One key data point that reinforces our confidence in the pace and success of this transition is the sales rep turnover rates, which remain at healthy single-digit levels. Moving on to our second priority, operational excellence. Over the last several years, we have improved manufacturing efficiency through SKU rationalization, technology advancements, and better planning. With demand continuing to grow, we are reshaping our U.S. manufacturing network to make it more nimble and efficient. This effort includes closing select underutilized manufacturing sites and consolidating operations into several facilities in Warsaw, Indiana, home to our global headquarters. We're also reinvesting in our Warsaw facilities, bringing in more advanced manufacturing processes. Together, these actions reflect our continued commitment to both Warsaw and US manufacturing. At the same time, we continue to consolidate our international manufacturing footprint into lower cost geographies while working with third-party experts to thoughtfully implement artificial intelligence capabilities. All of these initiatives are designed to address and improve our operating expense cost base, which at 46% OPEX to sales leaves room for dramatic improvement. We expect these strategies will improve flexibility, help us meet growing demand more efficiently and provide a long-term margin tailwind as the work progresses. Our third priority is innovation and diversification. We remain committed to investing both organically and inorganically to diversify our portfolio and increase our exposure to faster-growing markets. As part of this strategy, we have launched a strategic venture platform focused on identifying and investing in early-stage technologies with deep potential to redefine the standard of care. Beyond capital, we will leverage Zimmer Biomed's strong capabilities across R&D, clinical, regulatory, and commercialization to help accelerate the development and adoption of these exciting innovations. By expanding access to breakthrough technologies, this strategy reinforces our strong commitment to alleviating pain and improving the quality of life for people around the world. While early in the process, we are already evaluating several differentiated technologies to invest in and expect the number to grow in quarters to come. We genuinely believe that the combination of all organic innovation programs, the advancement of this new venture platform, plus the work in our partnership with Deerfield Management and HSS, a $300 million investment commitment over eight years will accelerate our WMGAR weighted average market growth rates towards an aspiration of 6% by the end of the decade. Beyond these endeavors, we remain committed to responsible M&A to accelerate all diversification efforts, pursuing deals that can replicate the strong success of our Paragon 28 acquisition. In summary, Our results reflect the strength of a diversified global business with two-thirds of the portfolio growing at upper single-digit or double-digit rates, as evidenced by strong results in HIPS, SET, and technology and data. We are highly encouraged by the progress that we are making as an organization, while we also understand that there is still room to improve. Our focus now is on finishing the year strong and entering 2027 from a position of strength with the objective of delivering accelerated performance leveraging the great transformational work that we have done in 2026. With that, I'll turn the call over to Paul. Thank you.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-